IL143935A - Bis-sulfonamides - Google Patents

Bis-sulfonamides

Info

Publication number: IL143935A
Authority: IL; Israel
Prior art keywords: lower alkyl; heteroaryl; aryl; heterocyclyl; alkyl
Prior art date: 1999-09-03

Application number

IL14393500A

Other languages

English (en)

Other versions

IL143935A0 (en

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-03

Filing date

2000-08-16

Publication date

2005-08-31

2000-08-16 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2002-04-21 Publication of IL143935A0 publication Critical patent/IL143935A0/xx

2005-08-31 Publication of IL143935A publication Critical patent/IL143935A/xx

Links

229940124530 sulfonamide Drugs 0.000 title abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 31
125000003282 alkyl amino group Chemical group 0.000 abstract 6
125000003342 alkenyl group Chemical group 0.000 abstract 5
125000003545 alkoxy group Chemical group 0.000 abstract 5
125000004414 alkyl thio group Chemical group 0.000 abstract 5
125000001072 heteroaryl group Chemical group 0.000 abstract 5
125000003118 aryl group Chemical group 0.000 abstract 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
102000017914 EDNRA Human genes 0.000 abstract 3
101150062404 EDNRA gene Proteins 0.000 abstract 3
102000017930 EDNRB Human genes 0.000 abstract 3
101150001833 EDNRB gene Proteins 0.000 abstract 3
125000000304 alkynyl group Chemical group 0.000 abstract 3
125000000623 heterocyclic group Chemical group 0.000 abstract 3
-1 Sulfonamide compounds Chemical class 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
BCRJIIJVFJJYRD-UHFFFAOYSA-N n-[3-[6-[(4-tert-butylphenyl)sulfonylamino]-2-cyclopropyl-5-(2-methoxyphenoxy)pyrimidin-4-yl]oxypropyl]thiophene-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C2CC2)OCCCNS(=O)(=O)C=2SC=CC=2)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 BCRJIIJVFJJYRD-UHFFFAOYSA-N 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
102000002045 Endothelin Human genes 0.000 abstract 1
108050009340 Endothelin Proteins 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000003257 anti-anginal effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002460 anti-migrenic effect Effects 0.000 abstract 1
230000002869 anti-sickling effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
229940124574 antisickling agent Drugs 0.000 abstract 1
125000001769 aryl amino group Chemical group 0.000 abstract 1
125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
125000005110 aryl thio group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
238000012875 competitive assay Methods 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
230000002439 hemostatic effect Effects 0.000 abstract 1
125000005241 heteroarylamino group Chemical group 0.000 abstract 1
125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
125000005150 heteroarylsulfinyl group Chemical group 0.000 abstract 1
125000005368 heteroarylthio group Chemical group 0.000 abstract 1
125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
125000004468 heterocyclylthio group Chemical group 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
230000001861 immunosuppressant effect Effects 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Glass Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Photoreceptors In Electrophotography (AREA)

IL14393500A 1999-09-03 2000-08-16 Bis-sulfonamides IL143935A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP9906485		1999-09-03
EP0001222		2000-02-15
PCT/EP2000/007999 WO2001017976A1 (en)	1999-09-03	2000-08-16	Bis-sulfonamides

Publications (2)

Publication Number	Publication Date
IL143935A0 IL143935A0 (en)	2002-04-21
IL143935A true IL143935A (en)	2005-08-31

Family

ID=8167417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14393500A IL143935A (en)	1999-09-03	2000-08-16	Bis-sulfonamides

Country Status (14)

Country	Link
US (1)	US6596719B1 (de)
EP (1)	EP1137642B1 (de)
CN (1)	CN100424079C (de)
AT (1)	ATE380180T1 (de)
AU (1)	AU775194B2 (de)
CA (1)	CA2361402C (de)
DE (1)	DE60037308T2 (de)
ES (1)	ES2295048T3 (de)
HU (1)	HUP0201402A3 (de)
IL (1)	IL143935A (de)
NO (1)	NO20013586D0 (de)
NZ (1)	NZ512526A (de)
WO (1)	WO2001017976A1 (de)
ZA (1)	ZA200105130B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6720322B2 (en) *	1999-12-22	2004-04-13	Actelion Pharamceuticals Ltd.	Butyne diol derivatives
JP2003527369A (ja) *	2000-03-13	2003-09-16	イーライ・リリー・アンド・カンパニー	スルホンアミド誘導体
US6387915B2 (en)	2000-05-31	2002-05-14	Pfizer Inc.	Isoxazole-sulfonamide endothelin antagonists
WO2002053557A1 (en) *	2000-12-18	2002-07-11	Actelion Pharmaceuticals Ltd	Novel sulfamides and their use as endothelin receptor antagonists
EP1243262B1 (de)	2001-03-20	2006-05-31	Schwarz Pharma Ag	Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de)	2001-03-21	2003-07-24	Schwarz Pharma Ag	Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US7323465B2 (en) *	2002-01-02	2008-01-29	Actelion Pharmaceuticals Ltd.	Alkansulfonamides as endothelin antagonists
WO2005053667A1 (en)	2003-12-02	2005-06-16	Schwarz Pharma Ag	Novel use of peptide compounds for treating central neuropathic pain
ES2391636T3 (es)	2004-03-05	2012-11-28	F. Hoffmann-La Roche Ag	Diaminopirimidinas como antagonistas de P2X3 y P2X2/3
KR20070007931A (ko)	2004-04-16	2007-01-16	쉬바르츠파르마에이지	만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (de)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
WO2006021412A2 (en)	2004-08-27	2006-03-02	Schwarz Pharma Ag	Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
WO2007025901A1 (en)	2005-09-01	2007-03-08	F. Hoffmann-La Roche Ag	Diaminopyrimidines as p2x3 and p2x2/3 modulators
JP4850912B2 (ja)	2005-09-01	2012-01-11	エフ．ホフマン−ラロシュアーゲー	Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン
ES2612890T3 (es)	2005-09-01	2017-05-19	F. Hoffmann-La Roche Ag	Diaminopirimidinas como moduladores de P2X3 y P2X2/3
US8735356B2 (en)	2006-06-15	2014-05-27	Ucb Pharma Gmbh	Anticonvulsant combination therapy
AR062501A1 (es)	2006-08-29	2008-11-12	Actelion Pharmaceuticals Ltd	Composiciones terapeuticas
MX2010001837A (es)	2007-08-17	2010-03-10	Actelion Pharmaceuticals Ltd	Derivados de 4-pirimidinasulfamida.
CN101279948B (zh) *	2008-03-14	2010-08-11	苏州博鸿化工技术有限公司	4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法
CN111407767B (zh) *	2020-03-28	2021-05-25	中山大学	一种磺胺间甲氧嘧啶衍生物在制备抗肿瘤药物中的应用
CN112778215B (zh) *	2021-01-29	2023-06-20	中国医科大学	2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用
CN112898208B (zh) *	2021-01-29	2023-06-20	中国医科大学	苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7310889A (de) *	1972-08-12	1974-02-14
CA2162630C (en) *	1994-11-25	2007-05-01	Volker Breu	Sulfonamides
TW313568B (de)	1994-12-20	1997-08-21	Hoffmann La Roche
US5739333A (en) *	1995-05-16	1998-04-14	Tanabe Seiyaku Co., Ltd.	Sulfonamide derivative and process for preparing the same
US5939446A (en) *	1996-04-09	1999-08-17	Bristol-Myers Squibb Co.	Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists

2000
- 2000-08-16 ES ES00956456T patent/ES2295048T3/es not_active Expired - Lifetime
- 2000-08-16 US US10/031,555 patent/US6596719B1/en not_active Expired - Fee Related
- 2000-08-16 WO PCT/EP2000/007999 patent/WO2001017976A1/en not_active Ceased
- 2000-08-16 CN CN00802515.0A patent/CN100424079C/zh not_active Expired - Fee Related
- 2000-08-16 AT AT00956456T patent/ATE380180T1/de not_active IP Right Cessation
- 2000-08-16 EP EP00956456A patent/EP1137642B1/de not_active Expired - Lifetime
- 2000-08-16 NZ NZ512526A patent/NZ512526A/xx active Application Filing
- 2000-08-16 DE DE60037308T patent/DE60037308T2/de not_active Expired - Lifetime
- 2000-08-16 AU AU68391/00A patent/AU775194B2/en not_active Ceased
- 2000-08-16 CA CA002361402A patent/CA2361402C/en not_active Expired - Fee Related
- 2000-08-16 IL IL14393500A patent/IL143935A/xx not_active IP Right Cessation
- 2000-08-16 HU HU0201402A patent/HUP0201402A3/hu unknown
2001
- 2001-06-21 ZA ZA200105130A patent/ZA200105130B/en unknown
- 2001-07-20 NO NO20013586A patent/NO20013586D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2361402A1 (en)	2001-03-15
NZ512526A (en)	2004-01-30
EP1137642A1 (de)	2001-10-04
WO2001017976A1 (en)	2001-03-15
NO20013586L (no)	2001-07-20
IL143935A0 (en)	2002-04-21
HUP0201402A2 (en)	2002-08-28
AU775194B2 (en)	2004-07-22
CA2361402C (en)	2009-05-12
HUP0201402A3 (en)	2003-12-29
DE60037308T2 (de)	2008-10-30
CN1335839A (zh)	2002-02-13
ES2295048T3 (es)	2008-04-16
DE60037308D1 (de)	2008-01-17
AU6839100A (en)	2001-04-10
NO20013586D0 (no)	2001-07-20
CN100424079C (zh)	2008-10-08
US6596719B1 (en)	2003-07-22
EP1137642B1 (de)	2007-12-05
ZA200105130B (en)	2002-09-23
ATE380180T1 (de)	2007-12-15

Legal Events

Date	Code	Title	Description
2006-02-21	FF	Patent granted
2006-12-07	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL143935A0 (en)	2002-04-21	Bis-sulfonamides
AU3943189A (en)	1990-05-31	Peptides having bradykinin antagonist action
IL134905A0 (en)	2001-05-20	Novel intermediates for endothelin antagonistic pyrrolidine derivatives
PT1188768E (pt)	2009-08-13	Peptídeos antagonistas de lhrh
WO1996016981A3 (en)	1996-09-06	Peptide compounds for prevention and/or treatment of no-mediated diseases
IL148157A0 (en)	2002-09-12	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU6092490A (en)	1991-02-21	Peptides having bradykinin antagonist action
NO972559L (no)	1997-08-05	Nye dipeptid-p-amidinobenzylamider med N-terminale sulfonyl- eller aminosulfonylrester
EP0573218A3 (en)	1994-06-01	4-carboxyimidazoles as angiotensin ii antagonists and their thrapeutic use
GB9310095D0 (en)	1993-06-30	Therapeutic compounds
HUP0402282A2 (hu)	2005-02-28	Triazolo[1,5-a]kinolin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények
HU9801792D0 (en)	1998-09-28	4-aminopyrrole(3,2-d)pyrimidines as neuropeptide y receptor antagonists
ATE153671T1 (de)	1997-06-15	Peptide mit bombesin/grp-antagonistischer wirkung
ES2009266A6 (es)	1989-09-16	Procedimiento para la preparacion de un derivado del acido n-acetil-6-aminohexanoico.